Research Coverage of Japanese Listed Companies, Shared Research Inc

Shared Research

Research Coverage of Japanese Listed Companies

Shared Research Inc

Pioneering research coverage of Japanese listed companies. Now customizable and interactive for global institutional investors. Corporate access reimagined.

Equity Bottom-Up

<ul><li>CanBas reported no operating revenue in Q1 FY06/24, with an operating loss of JPY251mn and increased R&D expenses. </li><li>Total assets rose by JPY1.3bn due to fundraising, while liabilities saw a JPY9mn decrease in accounts payable. </li><li>The company anticipates JPY5.5bn costs for potential Phase 3 trials in Europe, with development period and costs under review.</li></ul>

CanBas reported no operating revenue in Q1 FY06/24, with an operating loss of JPY251mn and increased R&D expenses. Total assets rose by JPY1.3bn due to fundraising, while liabilities saw a JPY9mn decrease in accounts payable. The company anticipates JPY5.5bn costs for potential Phase 3 trials in Europe, with development period and costs under review.

Canbas Co Ltd (4575 JP): Q1 FY06/25 flash update

Japan

CanBas Company Ltd. is a biopharmaceutical company that develops anti-cancer drugs with fewer side effects.  The Company's core technologies include drugs that target the G2 checkpoint and a screening system to find selective abrogators of the G2 checkpoint.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Canbas Co Ltd (4575 JP): Q1 FY06/25 flash update

CanBas reported no operating revenue in Q1 FY06/24, with an operating loss of JPY251mn and increased R&D expenses. Total assets rose by...

Shared Research